Synthesis and evaluation of a novel series of phosphodiesterase IV inhibitors. A potential treatment for asthma

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 19, 1998, Pages 2629-2634

  Beasley, Steven C ^a   Cooper, Nicola ^a   Gowers, Lewis ^a   Gregory, Joanna P ^a   Haughan, Alan F ^a   Hellewell, Paul G ^c   Macari, David ^c   Miotla, Jadwiga ^c   Montana, John G ^a   Morgan, Trevor ^a   Naylor, Robert ^b   Runcie, Karen A ^a   Tuladhar, Bishwa ^b   Warneck, Julie B H ^a  

^a Chiroscience Ltd   (United Kingdom)

^b UNIVERSITY OF BRADFORD   (United Kingdom)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 QUINOLINECARBOXYLIC ACID DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; FLUMEQUINE; OXOLINIC ACID; PHOSPHODIESTERASE IV INHIBITOR; PIROMIDIC ACID; ROLIPRAM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTHMA; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; EOSINOPHILIA; FERRET; GUINEA PIG; NONHUMAN; ORAL DRUG ADMINISTRATION; VOMITING;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; AMIDES; ANIMALS; ANTI-ASTHMATIC AGENTS; CARBOXYLIC ACIDS; EOSINOPHILIA; GUINEA PIGS; PHOSPHODIESTERASE INHIBITORS; QUINOLONES; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA; CAVIA PORCELLUS; MUSTELA PUTORIUS FURO; SUS SCROFA;

EID: 17144463974     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00490-9     Document Type: Article

References (25)

1. 1. Higgs, G. Chemistry and Industry 1997, 827-830.
2. 2. Giembycz, M. A. Trends Pharmacol Sci. 1996, 17, 331-336.
3. 3. (a) Teixeira, M. M.; Gristwood, R. W.; Cooper, N.; Hellewell, P. G. Trends Pharmacol Sci. 1997, 18, 164-170
4. (b) de Brito, F. B.; Souness, J. E.; Warne, P. J. Emerging Drugs 1997, 2, 249-268.
5. 4. (a) Huhne, C.; Poli, G. B.; Huang, F-C.; Souness, J. E.; Djuric, S. W. Bioorg. Med. Chem. Lett. 1998, 8, 175-178
6. (b) Piaz, V. D.; Giovannoni, M. P.; Castellana, C.; Palacios, J. M.; Beleta, J.; Domenech, T.; Segarra, V. J. Med. Chem. 1997, 40, 1417-1421
7. (c) Chambers, R. J.; Marfat, A.; Cheng, J. B.; Cohan, V. L.; Damon, D. B.; Duplantier, A. J.; Hibbs, T. A.; Jenkinson, T. H.; Johnson, K. L.; Kraus, K. G.; Pettipher, E. R.; Salter, E. D.; Shirley, J. T.; Umland, J. P. Bioorg. Med. Chem. Lett. 1997, 7, 739-744
8. (d) Duplantier, A. J.; Biggers, M. S.; Chambers, R. J.; Cheng, J. B.; Cooper, K.; Damon, D. B.; Eggler, J. F.; Kraus, K. G.; Marfat, A.; Masamune, H.; Pillar, J. S.; Shirley, J. T.; Umland, J. P.; Watson, J. W. J. Med. Chem. 1996, 39, 120-125
9. (e) Stafford, J. A.; Valvano, N. L.; Feldman, P. L.; Brawley, E. S.; Cowan, D. J.; Domanico, P. L.; Leesnitzer, M. A.; Rose, D. A.; Stinpson, S. A,; Strickland, A. B.; Unwalla, R. J.; Verghese, M. W. Bioorg. Med. Chem. Lett. 1995, 5, 1977-1982
10. (f) Masamune, H.; Cheng, J. B.; Cooper, K.; Eggler, J. F.; Marfat, A.; Marshall, S. C.; Shirley, J. T.; Tickner, J. E.; Umland, J. P.; Vazquez, E. Bioorg. Med. Chem. Lett. 1995, 5, 1965-1968
11. (g) Cheng, J. B.; Cooper, K.; Duplantier, A. J.; Eggler, J. F.; Kraus, K. G.; Marshall, S. C.; Marfat, A.; Masamune, H.; Shirley, J. T.; Tickner, J. E.; Umland, J. P. Bioorg. Med. Chem. Lett. 1995, 5, 1969-1972.
12. 5. Zeller, E.; Stief, H. J.; Pflug, B.; Sastre, Y.; Hernandez, M. Pharmacopsychiatry 1988, 59, 358-369.
13. 6. Schwabe, U.; Miyake, M.; Ohga, Y.; Daly, J. Mol. Pharmacol. 1976, 12, 900.
14. 7. (a) Muller, T.; Engels, P.; Fozard, J. R. Trends Pharmacol Sci. 1996, 17, 294-298
15. (b) Kelly, J. J.; Barnes, P. J.; Giembycz, M. A. Biochem. 1996, 318, 425-436
16. (c) Jacobitz, S.; McLaughlin, M. M.; Livi, G. P.; Burman, M.; Torphy, T. J. Mol. Pharmacol. 1996, 50, 891-899.
17. 50 = 1.1μM and was inactive in the RBA assay at 10μM.
18. 9. Wentland, M. P. The New Generation of Quinolones; Siporin, C.; Heifetz, C. L.; Domagala, J. M., Eds.; Marcel Dekker: New York, 1990; pp 1-43.
19. 10. Kaminsky, D.; Meltzer, R. I. . J. Med. Chem. 1968, 11, 160-164.
20. 11. Thompson, W. J.; Terasaki, W. L.; Epstein, P. M.; Strada, S. J. Adv. Cyclic Nucleotide Res. 1979, 10, 69.
21. 12. Schneider, H. H.; Schmeichen, R.; Brezinski, M., Seidler, J. Eur. J. Pharmacol. 1997, 127, 105-115.
22. 13. (a) Teixeira, M. M.; Reynia, S.; Robinson, M.; Shock, A.; Williams, F. M.; Rossi, A. G.; Hellewell, P. G. Br. J. Parmacol 1994, 111, 811-818
23. (b) Teixeira, M. M.; Williams, F. M.; Hellewell, P. G. Br. J. Parmacol. 1993, 110, 416-422.
24. 14. The mediators used as inflammagens in the guinea pig skin eosinophilia model were platelet aggregating factor (PAF), Arachidonic acid (AA) and zymosan-activated plasma (ZAP). Additionally sensitisation to bovine gamma globulin followed by an id challenge of antisera results in a passive cutaneous anaphylactic (PCA) response.
25. 15. Costall, B.; Domeney, A. M.; Naylor, R. J; Tattersall, F. D. Neuropharmacology 1987, 26, 1321-1326.